-
31.发明公开公开(公告)号：US20240180821A1
公开(公告)日：2024-06-06
申请号：US18283807
申请日：2022-03-24
IPC分类号： A61K9/00 , A61K31/407 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/26 , A61K47/32 , A61K47/38 , A61K47/40
CPC分类号： A61K9/006 , A61K31/407 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/26 , A61K47/32 , A61K47/38 , A61K47/40
摘要： An orally disintegrating film composition of ketorolac is disclosed. The composition comprises of therapeutically effective concentration of ketorolac of about 10%-20% by total weight of the composition and one or more pharmaceutically acceptable excipients that include solubilizers, polymer, plasticizer, disintegrating agent, sweetening agent, cooling agent, flavouring agent, pH modulating agents, colouring agent and purified water.
-
公开(公告)号：US20240180819A1
公开(公告)日：2024-06-06
申请号：US18284284
申请日：2022-03-31
申请人： ACTIVE BIOTECH AB
发明人： Hans Wännman , Marie Törngren , Helena Eriksson , Andreas Buhl
IPC分类号： A61K9/00 , A61K31/4704 , A61K47/10 , A61K47/18 , A61K47/26 , A61K47/32 , A61K47/38 , A61P27/02
CPC分类号： A61K9/0048 , A61K31/4704 , A61K47/10 , A61K47/183 , A61K47/186 , A61K47/26 , A61K47/32 , A61K47/38 , A61P27/02
摘要： A pharmaceutical formulation comprising laquinimod or a pharmaceutically acceptable salt thereof as active ingredient, a pharmaceutically acceptable viscosity agent, a pharmaceutically acceptable tonicity adjusting agent, a pharmaceutically acceptable humectant, a pharmaceutically acceptable antioxidant, and a pharmaceutically acceptable pH regulating agent. The formulation is suitable for the treatment of ocular diseases by ocular administration, preferably topical ocular administration.
-
33.发明授权公开(公告)号：US11998555B2
公开(公告)日：2024-06-04
申请号：US17426765
申请日：2020-01-30
发明人： Alfredo Grossi , Britt Kostraba , Olatokumbo O. Luca Ogunleye , Shannon Terry , Franciscus Koppenhagen
IPC分类号： A61K31/635 , A61K47/10 , A61K47/18 , A61K47/32 , A61M5/142
CPC分类号： A61K31/635 , A61K47/10 , A61K47/18 , A61K47/32 , A61M5/14248
摘要： Disclosed herein, in part, are liquid pharmaceutical formulations comprising furosemide or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable excipients, and a pharmaceutically acceptable buffer. Methods of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof are also provided.
-
公开(公告)号：US20240173270A1
公开(公告)日：2024-05-30
申请号：US18460656
申请日：2023-09-04
发明人： Yonghua DONG , Yuan HE , Liangliang ZHAO , Miaoxia LI
CPC分类号： A61K31/045 , A61B18/06 , A61K9/06 , A61K9/16 , A61K47/32 , A61K49/0002 , A61B2018/00416 , A61B2018/00577
摘要： Disclosed are a pharmaceutical composition containing ethanol and a use thereof. The pharmaceutical composition can be used in vivo for animals, and is prepared from the following raw material: ethanol having a concentration no lower than 50% and a liquid ethanol thickener. The pharmaceutical composition containing ethanol provided in the present invention has high developability and sufficient fluidity without toxic side effect on normal tissues. The present invention does not solidify in blood and can break endothelial cells or mucous membrane superficial tissues so as to allow for permanent embolization.
-
35.发明授权公开(公告)号：US11993759B2
公开(公告)日：2024-05-28
申请号：US15768642
申请日：2016-10-13
申请人： BASF SE
发明人： Karl Kolter , Ralf Pelzer , Matthias Karl
IPC分类号： A61K8/02 , A23L27/00 , A23L27/20 , A61K8/34 , A61K8/81 , A61K9/20 , A61K47/10 , A61K47/32 , A61K47/34 , A61K47/46 , A61L9/01 , A61Q13/00 , C11B9/00 , C11D3/00 , C11D3/37 , C11D3/50
CPC分类号： C11B9/0015 , A23L27/2026 , A23L27/203 , A23L27/74 , A61K8/0287 , A61K8/34 , A61K8/817 , A61K8/8182 , A61K47/10 , A61K47/32 , A61K47/34 , A61K47/46 , A61L9/01 , A61Q13/00 , C11B9/0034 , C11D3/00 , C11D3/3776 , C11D3/3788 , C11D3/505 , A23V2002/00
摘要： An optically clear, solid water-soluble formulation of odorants and flavorings comprising at least one synthetically prepared odorant and flavoring, in which the odorants and flavorings are embedded homogeneously in a polymer matrix based on polyvinyllactams.
-
公开(公告)号：US20240165102A1
公开(公告)日：2024-05-23
申请号：US18330238
申请日：2023-06-06
发明人： Andrew Finn , Niraj Vasisht
IPC分类号： A61K31/485 , A61K9/00 , A61K9/70 , A61K31/46 , A61K31/4748 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/22 , A61K47/32 , A61K47/38
CPC分类号： A61K31/485 , A61K9/006 , A61K9/7007 , A61K31/46 , A61K31/4748 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/22 , A61K47/32 , A61K47/38
摘要： The present invention provides abuse deterrent mucoadhesive devices for delivery of buprenorphine. Each device comprises a mucoadhesive layer and a backing layer, and the pH in each layer is selected, such that absorption of buprenorphine is maximized.
-
公开(公告)号：US11986460B2
公开(公告)日：2024-05-21
申请号：US16695710
申请日：2019-11-26
发明人： Satishkumar Jain , Parminder Singh Sidhu , Paul Robinson , Madhura Rege , Sundareswarakumar Chellaswamy
摘要： The present invention relates to a solid pharmaceutical preparation comprising α-lipoic acid, dicalcium phosphate and a binder. The solid pharmaceutical preparation has an improved stability and thereby improved bioavailability.
-
公开(公告)号：US20240156739A1
公开(公告)日：2024-05-16
申请号：US18231054
申请日：2023-08-07
发明人： Mohamed Albed Alhnan
IPC分类号： A61K9/20 , A61K9/00 , A61K47/10 , A61K47/32 , A61K47/38 , B29C64/118 , B29C64/209 , B29C64/245 , B29C64/314 , B29C64/393 , B33Y50/02 , B33Y70/00
CPC分类号： A61K9/2095 , A61K9/0087 , A61K47/10 , A61K47/32 , A61K47/38 , B29C64/118 , B29C64/209 , B29C64/245 , B29C64/314 , B29C64/393 , B33Y50/02 , B33Y70/00 , B29K2105/0035
摘要： The present invention utilizes 3D printing technology, specifically fused filament fabrication (FFF) 3D printing, to produce solid dosage forms, such as pharmaceutical tablets. The production process utilizes novel printing filaments, typically on a spool, which contain the active ingredient. Such active-containing filaments have proved to be extremely robust and the principles outlined in the present disclosure provide access to a variety of viable formulations directly from a 3D printer. This, for the first time, affords a viable means for the in situ (e.g. within a pharmacy) 3D printing of personalized medicines tailored to a patient's needs. The invention also relates to purpose-built software for operating the printing apparatus, as well as local, national and global systems for monitoring the real time operation of a plurality of printing apparati to enable facile detection of malfunctions, thereby making regulatory approval viable and facilitating regulatory compliance.
-
公开(公告)号：US11980685B1
公开(公告)日：2024-05-14
申请号：US18088375
申请日：2022-12-23
发明人： Nilesh Parikh , William Hite
CPC分类号： A61K9/0053 , A61K9/08 , A61K31/423 , A61K47/02 , A61K47/26 , A61K47/32
摘要： Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain an amount of a tafamidis of from 0.5 mg/ml to 20 mg/ml, water, and an amount of an alkaline pH modifier that yields a content of the tafamidis solubilized in the water of from 0.5 mg/ml to 19.8 mg/ml.
-
公开(公告)号：US11980623B2
公开(公告)日：2024-05-14
申请号：US17474322
申请日：2021-09-14
IPC分类号： A61K31/551 , A61K9/20 , A61K47/32 , A61K47/38
CPC分类号： A61K31/551 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K47/32 , A61K47/38
摘要： The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant.
-
-
-
-
-
-
-
-
-
搜索结果
6556 条记录 (耗时 0.032 秒)
